New eye drops aim to ease painful corneal scratches in rare skin disease
NCT ID NCT07016750
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an eye drop called KB803 in 16 people aged 6 months and older with dystrophic epidermolysis bullosa (DEB), a rare genetic condition causing fragile skin and recurrent corneal abrasions. Participants will receive both KB803 and a placebo in random order to see if the drops reduce the number of days with corneal abrasion symptoms and eye pain. The goal is to find a safe treatment that helps manage this painful eye complication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEB - DYSTROPHIC EPIDERMOLYSIS BULLOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
-
Mission Dermatology Center
RECRUITINGRancho Santa Margarita, California, 92688, United States
Contact Email: •••••@•••••
-
Skin Research Institute
RECRUITINGCoral Gables, Florida, 33146, United States
Contact Email: •••••@•••••
-
Texas Dermatology and Laser Specialists
RECRUITINGSan Antonio, Texas, 78218, United States
-
UMass Memorial Medical Center
RECRUITINGWorcester, Massachusetts, 01605, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene therapy for 'Butterfly Skin' disease tracked for 15 years in major safety registry
- Anti-Inflammatory drug may ease swallowing in rare skin disease
- New hope for blistering skin diseases: drug targets antibodies to heal wounds
- Stanford launches study to better understand rare blistering skin disease
- Gene therapy gel aims to stop skin cancer from coming back in RDEB patients
- New cream could help kids with 'Butterfly Skin' heal faster